Topical drug delivery devices: A review

被引:64
|
作者
Bertens, Christian J. F. [1 ,2 ,3 ]
Gijs, Marlies [1 ,2 ,3 ]
van den Biggelaar, Frank J. H. M. [1 ,3 ]
Nuijts, Rudy M. M. A. [1 ,3 ]
机构
[1] Univ Med Ctr, Univ Eye Clin Maastricht, Dept Ophthalmol, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, Sch Mental Hlth & Neurosci MHeNS, Dept Neurosci, Univ Singel 50, NL-6229 ER Maastricht, Netherlands
[3] Chemelot Inst Sci & Technol InSciTe, Urmonderbaan 20F, NL-6167 RD Geleen, Netherlands
关键词
Ophthalmic drug delivery; Eye drop replacement; Patient compliance; Drug delivery routes; Ocular inserts; Ophthalmic drug delivery devices; SUSTAINED-RELEASE DEXAMETHASONE; AQUEOUS-HUMOR DYNAMICS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; THERAPEUTIC CONTACT-LENSES; RANDOMIZED CLINICAL-TRIAL; CYSTOID MACULAR EDEMA; IN-VITRO; CATARACT-SURGERY; MEDICAL DEVICE; OCULAR INSERT;
D O I
10.1016/j.exer.2018.01.010
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
For the treatment and prevention of ocular diseases, most patients are treated with conventional drug delivery formulations such as eye drops or ointments. However, eye drops and ointments suffer from low patient compliance and low effective drug concentration at the target site. Therefore, new medical devices are being explored to improve drug delivery to the eye. Over the years, various delivery devices have been developed including resorbable devices, oval- and ring-shaped devices, rod-shaped devices, punctum plugs, contact lenses and corneal shields. Only a few devices (eg. Mydriasert(center dot), Ozurdex(center dot), Surodex(center dot), Iluvien(center dot), Lacrisert(center dot) and Retisert(center dot)) have made it to the market while others are being investigated in clinical trials. Altogether, there is a need for enhanced topical drug delivery. Only by working together (academia, industry and authorities) and by exploring parallel strategies (new drug delivery devices, enhanced drug formulations, better understanding of the pharmacokinetic properties), the therapeutic effect of drug treatments can be improved.
引用
收藏
页码:149 / 160
页数:12
相关论文
共 50 条
  • [31] TOPICAL IONTOPHORETIC DRUG-DELIVERY IN-VIVO - HISTORICAL DEVELOPMENT, DEVICES AND FUTURE PERSPECTIVES
    SINGH, J
    MAIBACH, HI
    DERMATOLOGY, 1993, 187 (04) : 235 - 238
  • [32] Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
    Per Gisle Djupesland
    Drug Delivery and Translational Research, 2013, 3 : 42 - 62
  • [33] Assessment of drug delivery devices
    Batista, Elsa
    Almeida, Nelson
    Furtado, Andreia
    Filipe, Eduarda
    Sousa, Luis
    Martins, Rui
    Lucas, Peter
    Petter, Harm Tido
    Snijder, Roland
    Timmerman, Annemoon
    BIOMEDICAL ENGINEERING-BIOMEDIZINISCHE TECHNIK, 2015, 60 (04): : 347 - 357
  • [34] Using drug delivery devices
    Lilley, LL
    Guanci, R
    AMERICAN JOURNAL OF NURSING, 1996, 96 (10) : 14 - 14
  • [35] MEMS devices for drug delivery
    Lee, Hyunjoo J.
    Choi, Nakwon
    Yoon, Eui-Sung
    Cho, Il-Joo
    ADVANCED DRUG DELIVERY REVIEWS, 2018, 128 : 132 - 147
  • [36] MICROCAPSULES AS DRUG DELIVERY DEVICES
    THIES, C
    CRC CRITICAL REVIEWS IN BIOMEDICAL ENGINEERING, 1982, 8 (04): : 335 - 383
  • [37] TRANSDERMAL DRUG DELIVERY DEVICES
    LEDGER, PW
    NICHOLS, KC
    CLINICS IN DERMATOLOGY, 1989, 7 (03) : 25 - 31
  • [38] Respiratory drug delivery devices
    Lenney, W
    BRITISH JOURNAL OF GENERAL PRACTICE, 1996, 46 (409): : 492 - 493
  • [39] IONTOPHORETIC DEVICES FOR DRUG DELIVERY
    TYLE, P
    PHARMACEUTICAL RESEARCH, 1986, 3 (06) : 318 - 326
  • [40] TRANSDERMAL DRUG DELIVERY DEVICES
    WOLLINA, U
    MEDIZINISCHE WELT, 1991, 42 (10): : 877 - 880